Faculty Opinions recommendation of Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718532439.793525446 ◽

2016 ◽

Author(s):

Mark Obermann ◽

Dagny Holle

Keyword(s):

Monoclonal Antibody ◽

Calcitonin Gene Related Peptide ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Calcitonin Gene

Get full-text (via PubEx)

Faculty Opinions recommendation of Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718532439.793500323 ◽

2014 ◽

Author(s):

Shuu-Jiun Wang

Keyword(s):

Monoclonal Antibody ◽

Calcitonin Gene Related Peptide ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Calcitonin Gene

Get full-text (via PubEx)

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

The Lancet Neurology ◽

10.1016/s1474-4422(14)70128-0 ◽

2014 ◽

Vol 13 (9) ◽

pp. 885-892 ◽

Cited By ~ 227

Author(s):

David W Dodick ◽

Peter J Goadsby ◽

Egilius L H Spierings ◽

Joel C Scherer ◽

Steven P Sweeney ◽

...

Keyword(s):

Monoclonal Antibody ◽

Calcitonin Gene Related Peptide ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Calcitonin Gene

Get full-text (via PubEx)

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(14)70209-1 ◽

2014 ◽

Vol 13 (11) ◽

pp. 1100-1107 ◽

Cited By ~ 225

Author(s):

David W Dodick ◽

Peter J Goadsby ◽

Stephen D Silberstein ◽

Richard B Lipton ◽

Jes Olesen ◽

...

Keyword(s):

Episodic Migraine ◽

Calcitonin Gene Related Peptide ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Phase 2 Trial ◽

Calcitonin Gene

Get full-text (via PubEx)

Faculty Opinions recommendation of Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.720592850.793525445 ◽

2016 ◽

Author(s):

Mark Obermann ◽

Dagny Holle

Keyword(s):

Episodic Migraine ◽

Calcitonin Gene Related Peptide ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Phase 2 Trial ◽

Calcitonin Gene

Get full-text (via PubEx)

Faculty Opinions recommendation of Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734858436.793573735 ◽

2020 ◽

Author(s):

Graham Pawelec

Keyword(s):

Monoclonal Antibody ◽

Influenza A ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy

Get full-text (via PubEx)

Safety and Efficacy of Monoclonal Antibody VIS410 in Adults with Uncomplicated Influenza A Infection: Results from a Randomised, Double-Blind, Placebo-Controlled Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271424 ◽

2018 ◽

Author(s):

Ellie Hershberger ◽

Susan Sloan ◽

Kristin Narayan ◽

Catherine A. Hay ◽

Patrick Smith ◽

...

Keyword(s):

Monoclonal Antibody ◽

Influenza A ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

EBioMedicine ◽

10.1016/j.ebiom.2018.12.051 ◽

2019 ◽

Vol 40 ◽

pp. 574-582 ◽

Cited By ~ 29

Author(s):

Ellie Hershberger ◽

Susan Sloan ◽

Kristin Narayan ◽

Catherine A. Hay ◽

Patrick Smith ◽

...

Keyword(s):

Monoclonal Antibody ◽

Influenza A ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy

Get full-text (via PubEx)

Faculty Opinions recommendation of A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717983097.793473289 ◽

2013 ◽

Author(s):

Walter Hasibeder

Keyword(s):

Severe Sepsis ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

The Journal of Headache and Pain ◽

10.1186/1129-2377-15-s1-g10 ◽

2014 ◽

Vol 15 (S1) ◽

Cited By ~ 1

Author(s):

P Goadsby ◽

D Dodick ◽

E Spierings ◽

J Scherer ◽

S Sweeney ◽

...

Keyword(s):

Monoclonal Antibody ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

OP0024 Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1707 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 60.3-61

Author(s):

N. Damjanov ◽

M. Tlustochowicz ◽

J. Aelion ◽

A. Dimic ◽

M. Greenwald ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)